- Home
- WATT vs BCLI Comparison
WATT vs BCLI Comparison
Compare WATT & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- BCLI
- Stock Information
- Founded
- WATT 2012
- BCLI 2000
- Country
- WATT United States
- BCLI United States
- Employees
- WATT N/A
- BCLI N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WATT Technology
- BCLI Health Care
- Exchange
- WATT Nasdaq
- BCLI Nasdaq
- Market Cap
- WATT 9.1M
- BCLI 9.9M
- IPO Year
- WATT 2014
- BCLI N/A
- Fundamental
- Price
- WATT $0.42
- BCLI $1.73
- Analyst Decision
- WATT Strong Buy
- BCLI Strong Buy
- Analyst Count
- WATT 2
- BCLI 1
- Target Price
- WATT $2.25
- BCLI $30.00
- AVG Volume (30 Days)
- WATT 929.8K
- BCLI 41.1K
- Earning Date
- WATT 03-27-2025
- BCLI 03-31-2025
- Dividend Yield
- WATT N/A
- BCLI N/A
- EPS Growth
- WATT N/A
- BCLI N/A
- EPS
- WATT N/A
- BCLI N/A
- Revenue
- WATT $431,184.00
- BCLI N/A
- Revenue This Year
- WATT $95.75
- BCLI N/A
- Revenue Next Year
- WATT $834.07
- BCLI N/A
- P/E Ratio
- WATT N/A
- BCLI N/A
- Revenue Growth
- WATT N/A
- BCLI N/A
- 52 Week Low
- WATT $0.28
- BCLI $1.05
- 52 Week High
- WATT $2.70
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- WATT 44.73
- BCLI 40.62
- Support Level
- WATT $0.42
- BCLI $1.69
- Resistance Level
- WATT $0.49
- BCLI $1.93
- Average True Range (ATR)
- WATT 0.04
- BCLI 0.11
- MACD
- WATT 0.00
- BCLI -0.00
- Stochastic Oscillator
- WATT 29.60
- BCLI 16.67
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.